Company update with Ulf Jungnelius, CEO

Watch the interview where Ulf Jungnelius gives a status update on
arfolitixorin, the milestones in the short and long term and the upcoming rights issue >>

Arfolitixorin - a drug candidate
for treatment of colorectal cancer

See how arfolitixorin
works in cancer cells

See the animation >>

The global Phase III AGENT study

The AGENT study with arfolitixorin

is ongoing at more than 80 hospitals

in The US, Canada, Europe, Australia and Japan

Previous

Next

Startpage 2

Press releases & Latest news

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

May 14, 2020 by

GOTHENBURG, Sweden, May 14, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the…

Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

May 7, 2020 by

GOTHENBURG, Sweden, May 7, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the…

Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data

Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data

May 6, 2020 by Admin Isofol

Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM),…

Upcoming Events

June 24, 2020 - June 24, 2020
Annual General Meeting 2020
August 21, 2020 - August 21, 2020
Interim Report Q2 2020
November 13, 2020 - November 13, 2020
Interim Report Q3 2020